By MARCIA DUNN/AP Aerospace Writer

CAPE CANAVERAL, Fla. (AP) — Boeing's new Starliner capsule went off course after launch Friday and won't dock with the International Space Station during its first test flight.

It was supposed to be a crucial dress rehearsal for next year's inaugural launch with astronauts.

The blastoff from Cape Canaveral, Florida, went flawlessly as the Atlas V rocket lifted off with the Starliner capsule. But a half-hour into the flight, Boeing reported that the capsule didn't get into the right orbit to reach the space station. The capsule is still in space and will be brought back to Earth, landing in New Mexico as early as Sunday.

Boeing is one of two companies hired by NASA to launch astronauts from the U.S. The space agency has been relying on Russian rockets to travel to the space station since the retirement of the space shuttle almost nine years ago.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below:

Boeing's new Starliner capsule ran into trouble and went off course in orbit minutes after blasting off Friday on its first test flight, a crucial dress rehearsal for next year's inaugural launch with astronauts.

Everything went flawlessly as the Atlas V rocket soared with the Starliner just before sunrise. But a half-hour into the flight, Boeing reported that the capsule didn't get into the position needed to get to the International Space Station.

Officials stressed that the capsule was in a safe and stable orbit. NASA Administrator Jim Bridenstine said in a tweet that the capsule burned up more fuel than planned and controllers were using the capsule's thrusters to raise its orbit.

With less fuel onboard, it put the rest of the flight in jeopardy. The Starliner was supposed to reach the space station on Saturday and stay for a week.

Thousands of spectators jammed the area, eager to witness Starliner's premiere flight. The United Launch Alliance rocket blasted off from Cape Canaveral Air Force Station and was visible for at least five minutes, its white contrail a brilliant contrast against the dark sky. The mood quickly turned somber as news of the setback trickled out. NASA officials deferred to Boeing for updates.

“Safe and stable is the important thing right now,” Boeing spokeswoman Kelly Kaplan told reporters.

This was Boeing's chance to catch up with SpaceX, NASA's other commercial crew provider that successfully completed a similar demonstration last March. SpaceX has one last hurdle — a launch abort test — before carrying two NASA astronauts in its Dragon capsule, possibly by spring.

A successful Starliner demo could have seen Boeing launching astronauts by summer. But that might not be possible now.

The U.S. needs companies competing like this, NASA Administrator Jim Bridenstine said Thursday, to drive down launch costs, boost innovation and open space up to more people. He stressed the need for more than one company in case of problems that kept one grounded.

The space agency handed over station deliveries to private businesses, first cargo and then crews, in order to focus on getting astronauts back to the moon and on to Mars.

Commercial cargo ships took flight in 2012, starting with SpaceX. Crew capsules were more complicated to design and build, and parachute and other technical problems pushed the first launches from 2017 to now next year. Last April, a SpaceX crew capsule exploded during a ground test.

It's been nearly nine years since NASA astronauts have launched from the U.S. The last time was July 8, 2011, when Atlantis — now on display at Kennedy Space Center — made the final space shuttle flight.

Since then, NASA astronauts have traveled to and from the space station via Kazakhstan, courtesy of the Russian Space Agency. The Soyuz rides have cost NASA up to $86 million apiece.

Chris Ferguson commanded that last shuttle mission. Now a test pilot astronaut for Boeing and one of the Starliner's key developers, he's assigned to the first Starliner crew with NASA's Mike Fincke and Nicole Mann. All three were at control centers to watch the launch.

Built to accommodate seven, the white capsule with black and blue trim will typically carry four or five people. It's 16.5 feet (5 meters) tall with its attached service module and 15 feet (4.5 meters) in diameter.

For the test flight, the Starliner carried Christmas treats and presents for the six space station residents, hundreds of tree seeds similar to those that flew to the moon on Apollo 14, the original air travel ID card belonging to Boeing's founder and a mannequin named Rosie in the commander's seat.

The test dummy — named after the bicep-flexing riveter of World War II — wore a red polka dot hair bandanna just like the original Rosie and Boeing's custom royal blue spacesuit.

The flight was designed to test all systems, from the vibrations and stresses of liftoff to the Dec. 28 touchdown at the Army's White Sands Missile Range in New Mexico, with parachutes and airbags to soften the landing. Even the test dummy is packed with sensors.

On the eve of the flight, Bridenstine said he's "very comfortable" with Boeing, despite the prolonged grounding of the company's 737 Max jets. The spacecraft and aircraft sides of the company are different, he noted. Boeing has long been involved in NASA's human spacecraft program, from Project Mercury to the shuttle and station programs.

Boeing began preliminary work on the Starliner in 2010, a year before Atlantis soared for the last time.

In 2014, Boeing and SpaceX made the final cut. Boeing got more than $4 billion to develop and fly the Starliner, while SpaceX got $2.6 billion for a crew-version of its Dragon cargo ship.

NASA wants to make sure every reasonable precaution is taken with the capsules, designed to be safer than NASA's old shuttles.

“We're talking about human spaceflight,” Bridenstine cautioned. “It's not for the faint of heart. It never has been, and it's never going to be."

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Maker of First FDA-Approved Portable MRI Machine Hyperfine Goes Public
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
FDA Authorizes Pfizer's Covid-19 Treatment Pill Marking Pandemic Milestone
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home. Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Markets Continue to Feel Omicron Pressures
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
An Omicron Christmas, Student Loans & Love, Hate, Ate
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer COVID Treatment Pill Gets FDA Authorization
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
Semiconductor Industry Warns Shortage Could Last Deep Into 2022
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Nomi Health Closes $110 Million to Further Scale Its Direct Healthcare Model Nationwide
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
Delta Airlines CEO Calls for Shortened Quarantine Times Amid Staffing Shortage
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
Load More